Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEMOIN
2024-516918-37-00Phase 2Authorised
- Sponsor
- Institut du Cancer de Montpellier
- Start
- Sep 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temozolomide in diffuse low-grade glioma (LGG), sponsored by Institut du Cancer de Montpellier. Primary endpoint: Feasibility (participation and compliance rates). Planned start Sep 2024; status: authorised.
02
Drugs
temozolomide
03
Conditions
diffuse low-grade glioma (LGG)
Beyond the preview
Go deeper on 2024-516918-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516918-37-00.